PRNewswire (Fri, 14-Aug 4:30 PM ET)
PRNewswire (Fri, 14-Aug 4:30 PM ET)
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
PRNewswire (Wed, 12-Aug 8:01 AM ET)
Market Chameleon (Wed, 5-Aug 7:07 AM ET)
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
PRNewswire (Wed, 5-Aug 9:17 AM ET)
PRNewswire (Tue, 21-Jul 9:17 AM ET)
PRNewswire (Mon, 1-Jun 7:00 AM ET)
Market Chameleon (Thu, 5-Mar 5:33 AM ET)
Citius Oncology Prepares for Major ASH Conference Spotlight as LYMPHIR Launch Remains on Track
Market Chameleon (Wed, 26-Nov 6:08 AM ET)
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Citius Pharmaceuticals trades on the NASDAQ stock market under the symbol CTXR.
As of September 1, 2026, CTXR stock price was flat at $0.58 with 54,792 million shares trading.
CTXR has a beta of 2.71, meaning it tends to be more sensitive to market movements. CTXR has a correlation of 0.14 to the broad based SPY ETF.
CTXR has a market cap of $15.92 million. This is considered a Sub-Micro Cap stock.
Last quarter Citius Pharmaceuticals reported $1 million in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.02.
In the last 3 years, CTXR traded as high as $26.75 and as low as $.47.
The top ETF exchange traded funds that CTXR belongs to (by Net Assets): VXF.
CTXR has underperformed the market in the last year with a return of -56.4%, while the SPY ETF gained +19.5%. In the last 3 month period, CTXR fell short of the market, returning -11.4%, while SPY returned +1.2%. However, in the most recent 2 weeks CTXR has outperformed the stock market by returning +3.2%, while SPY returned -1.2%.
CTXR support price is $.54 and resistance is $.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTXR shares will trade within this expected range on the day.